Sugi Predict

Sugi Predict / Compounds / SCHEMBL2145333

SCHEMBL2145333

SCHEMBL2145333

Fc1ccc(C2CCCNC2)cc1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HTR3A P46098 1/20 0.53
▸ KCNH2 Q12809 2/20 0.51
▸ HTR2A P28223 2/20 0.51
▸ DRD2 P14416 2/20 0.51
▸ HTR2C P28335 1/20 0.51
▸ CYP2D6 P10635 1/20 0.50
▸ SLC6A2 P23975 1/20 0.50
▸ SLC6A4 P31645 1/20 0.50
▸ SLC6A3 Q01959 1/20 0.50
▸ MAPK11 Q15759 2/20 0.48
▸ MAPK14 Q16539 2/20 0.48
▸ MAPK13 O15264 1/20 0.48
▸ RAF1 P04049 1/20 0.48
▸ MAPK9 P45984 1/20 0.48
▸ MAPK12 P53778 1/20 0.48
▸ DRD3 P35462 1/20 0.47
▸ CHRM1 P11229 1/20 0.47
▸ HRH1 P35367 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24127465 1.00 HTR3A (0.53) HTR3AKCNH2HTR2ADRD2HTR2C
SCHEMBL25305280 1.00 HTR3A (0.53) HTR3AKCNH2HTR2ADRD2HTR2C
Hydrochloric Acid SCHEMBL567212 0.98 HTR3A (0.52) HTR3AKCNH2HTR2ADRD2HTR2C
SCHEMBL22778149 0.94 KCNH2 (0.55) HTR3AKCNH2HTR2ADRD2HTR2C
SCHEMBL2937820 0.90 HTR3A (0.66) HTR3AHTR2C
SCHEMBL1707108 0.90 HTR3A (0.66) HTR3AHTR2C
SCHEMBL1828844 0.90 HTR3A (0.66) HTR3AHTR2C
Hydrochloric Acid SCHEMBL21201476 0.88 HTR3A (0.63) HTR3AHTR2C
Hydrochloric Acid SCHEMBL29051162 0.88 HTR3A (0.63) HTR3AHTR2C
Hydrochloric Acid SCHEMBL1919231 0.88 HTR3A (0.63) HTR3AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227428-A1 AMIDO COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-07-20 — — US disclosed
US-20230227428-A1 AMIDO COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-07-20 — — US disclosed
US-20230227428-A1 AMIDO COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-07-20 — — US disclosed
CN-115634208-A Paroxetine sustained release tablet and preparation method thereof 上海宣泰医药科技股份有限公司 2023-01-24 — — CN disclosed
US-11345679-B2 Quaternary lactam compound and pharmaceutical use thereof SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO., LTD. (CN) 2022-05-31 — — US disclosed
WO-2022090711-A1 COMPOUNDS AS CD73 INHIBITORS AdoRx Therapeutics Limited (GB) 2022-05-05 — — WO disclosed
WO-2021253098-A1 AMIDO COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2021-12-23 — — WO disclosed
WO-2021253098-A1 AMIDO COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2021-12-23 — — WO disclosed
CN-113121527-A Tricyclic compound and use thereof 上海辉启生物医药科技有限公司 2021-07-16 — — CN disclosed
CN-112707857-A Method for preparing piperidine compound by hydrogen transfer reduction of pyridine compound 西南石油大学 2021-04-27 — — CN disclosed
US-20080255152-A1 DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2008-10-16 — — US disclosed
US-20080176883-A1 Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone ABBVIE INC. 2008-07-24 — — US disclosed
US-7381719-B2 Diaryl ethers as opioid receptor antagonist ELI LILLY AND COMPANY (US) 2008-06-03 — — US disclosed
WO-2008006703-A1 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS HIGH POINT PHARMACEUTICALS, LLC (US) 2008-01-17 — — WO disclosed
EP-1878721-A1 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors NOVO NORDISK A/S (DK) 2008-01-16 — — EP disclosed
CN-101061095-A Cycloalkyl piperidine tachykinin receptor antagonists MERCK & CO INC (US) 2007-10-24 — — CN disclosed
CN-1305852-C Diaryl ethers as opioid receptor antagonists LILLY CO ELI (US) 2007-03-21 — — CN disclosed
US-20060217372-A1 Diaryl ethers as opioid receptor antagonist ELI LILLY AND COMPANY 2006-09-28 — — US disclosed
EP-1562595-A1 DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-08-17 — — EP disclosed
WO-2004026305-A1 DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST ELI LILLY AND COMPANY (US) 2004-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176883-A1 Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone MIF, CCL5, CCR2 HTR3A 504/4885KCNH2 4222/4885HTR2A 1050/4885
US-20230227428-A1 AMIDO COMPOUNDS RIPK1, RIPK3, MLKL HTR3A 3838/4885KCNH2 4047/4885HTR2A 4619/4885
US-11345679-B2 Quaternary lactam compound and pharmaceutical use thereof F2, PCSK9, F9 HTR3A 4669/4885KCNH2 2362/4885HTR2A 4534/4885
US-20080255152-A1 DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS OPRM1, OPRD1, OPRL1 HTR3A 275/4885KCNH2 586/4885HTR2A 954/4885
US-20060217372-A1 Diaryl ethers as opioid receptor antagonist OPRM1, OPRL1, OPRD1 HTR3A 266/4885KCNH2 540/4885HTR2A 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.